Serum HIF-1α, IGF-1 and IGFBP-3 correlate to recurrence and overall survival in early-stage hepatocellular carcinoma patients

被引：0
|
作者：
Ding, Shujun [1 ]
Ding, Wei [2 ]
Zhang, Ye [3 ]
Chen, Yunbao [1 ]
Tang, Hongtao [1 ]
Jiang, Xiao [4 ]
Chen, Jun [1 ]
机构：
[1] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Ultrasonog, Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Intervent Radiol, Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Gen Surg, Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China
[4] Shanghai Yangpu Dist Shidong Hosp, Dept Ultrasonog, 999 Shiguang Rd, Shanghai 200438, Peoples R China
来源：
BIOMARKERS IN MEDICINE | 2024年 / 18卷 / 23期
关键词：
HCC; HIF-1; alpha; IGF-1; IGFBP-3; recurrence; GROWTH-FACTOR-I; FACTOR-BINDING PROTEIN-3; PROGNOSTIC IMPLICATIONS; INSULIN; CANCER; RESECTION; EXPRESSION; DIAGNOSIS; ABLATION; ACTIVATION;
D O I：
10.1080/17520363.2024.2421149
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Aim: Recurrence of hepatocellular carcinoma (HCC) after ultrasound-guided microwave ablation (UGMWA) was a critical issue. Therefore, it is significant to identify the role of hypoxia-inducible factor 1 alpha (HIF-1 alpha), insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) in recurrence.Materials & methods: HCC patients receiving UGMWA were divided into recurrence and no-recurrence groups. The preoperative and postoperative risk factors were compared between these two groups.Results: Preoperative and postoperative serum levels of HIF-1 alpha, IGF-1 and IGFBP-3 were closely associated with the recurrence of HCC. Serum HIF-1 alpha level was increased, while serum levels of IGF-1 and IGFBP-3 were decreased in HCC patients with recurrence.Conclusion: HIF-1 alpha, IGF-1 and IGFBP-3 were associated with and predicted the recurrence of HCC after UGMWA, respectively or in combination.
引用
收藏
页码：1027 / 1036
页数：10
相关论文
共 50 条
  • [1] IGF-1 and IGFBP-3 in patients with liver disease
    Wallek, Grit
    Friedrich, Nele
    Ittermann, Till
    Mayerle, Julia
    Voelzke, Henry
    Nauck, Matthias
    Spielhagen, Christin
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2013, 37 (01): : 13 - 20
  • [2] Serum IGF-1, IGF-2 and IGFBP-3 as Parameters in the Assessment of Liver Dysfunction in Patients with Hepatic Cirrhosis and in the Diagnosis of Hepatocellular Carcinoma
    Rehem, Rania Naguib Abdel Mouteleb Abdel
    El-Shikh, Wafaa Mohamed Hussein Mekky
    HEPATO-GASTROENTEROLOGY, 2011, 58 (107) : 949 - 954
  • [3] Serum IGF-1 and IGFBP-3 levels in subclinical hypothyroid women
    Balci, Huriye
    Erdem, Tijen Yesim
    Ugurlu, Serdal
    Yetkin, Demet Ozgul
    Bolayirli, I. Murat
    Hacibekiroglu, Munire
    Tasan, Ertugrul
    CENTRAL EUROPEAN JOURNAL OF MEDICINE, 2011, 6 (02): : 158 - 162
  • [4] Serum IGF-1 and IGFBP-3 levels in subclinical hypothyroid women
    Balci, H.
    Yesim, T. E.
    Bolayirli, I. M.
    Yetkin, D. O.
    Hacibekiroglu, M.
    Tasan, E.
    CLINICAL CHEMISTRY, 2006, 52 (06) : A85 - A85
  • [5] Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer
    Tas, Faruk
    Bilgin, Elif
    Tastekin, Didem
    Erturk, Kayhan
    Duranyildiz, Derya
    BIOMEDICAL REPORTS, 2016, 4 (05) : 609 - 614
  • [6] Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection
    Aleem, Eiman
    Elshayeb, Ayman
    Elhabachi, Nihal
    Mansour, Amal Refaat
    Gowily, Ahmed
    Hela, Asmaa
    ONCOLOGY LETTERS, 2012, 3 (03) : 704 - 712
  • [7] Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients
    Papadakis, Georgios Z.
    Mavroudis, Dimitrios
    Georgoulias, Vasilios
    Souglakos, John
    Alegakis, Athanasios K.
    Samonis, George
    Bagci, Ulas
    Makrigiannakis, Antonis
    Zoras, Odysseas
    GROWTH HORMONE & IGF RESEARCH, 2017, 33 : 28 - 34
  • [8] Plasma levels of growth factors (HGH, IGF-1 and IGFBP-3) in cirrhotic patients with or without hepatocellular carcinoma (HCC).
    Legoux, JL
    Georges, A
    Thibeault, R
    Lepoutre, A
    Laharie, D
    Cazorla, S
    Dubuc, J
    Bordenave, L
    Amouretti, M
    de Ledinghen, V
    Couzigou, P
    HEPATOLOGY, 2003, 38 (04) : 766A - 766A
  • [9] Genetic variability in IGF-1 and IGFBP-3 and body size in early life
    Poole, Elizabeth M.
    Tworoger, Shelley S.
    Hankinson, Susan E.
    Baer, Heather J.
    BMC PUBLIC HEALTH, 2012, 12
  • [10] Genetic variability in IGF-1 and IGFBP-3 and body size in early life
    Elizabeth M Poole
    Shelley S Tworoger
    Susan E Hankinson
    Heather J Baer
    BMC Public Health, 12
12345